Novo Nordisk A/S is facing significant competitive pressures as it nears the expiration of its semaglutide patent in India, paving the way for generics priced up to 50% lower. The company's stock has plummeted by 48% in 2025 and another 26% in 2026, largely due to fierce competition, particularly from Eli Lilly. Despite the FDA's recent approval of a higher-dose Wegovy, analysts caution that an impending pricing war could further challenge profit margins in the obesity drug market. In response, Novo is pivoting to strategic partnerships, notably with Hims & Hers Health, to enhance its market presence and reclaim lost share.
“The thesis for biopharma stocks may be evolving away from obesity for the first time in four years, says Jared Holz of @MizuhoAmericas.”
“Las farmacéuticas indias aprovecharon la expiración de la patente de Ozempic, el polémico medicamento para bajar de peso y tratar la diabetes de Novo Nordisk A/S, para lanzar versiones genéricas a precios reducidos en un país con la tercera mayor población con sobrepeso.”
“Novo Nordisk announced on Thursday that the U.S. Food and Drug Administration (FDA) approved a new 7.2 mg version of its blockbuster obesity therapy Wegovy as a treatment to lower extra body weight and maintain weight reduction in the long term.”
“So far, 16 leading drugmakers have agreed to lower U.S. prices of their brand-name medicines under Trump’s MFN policy. They include Lilly, Novo, AstraZeneca, and others.”
“Today, Novo Nordisk sells a weight loss pill -- approved late last year -- but Lilly's offers greater convenience.”
“Demand has been high, even surpassing supply at certain points, as tirzepatide and rival semaglutide, sold by Novo Nordisk, have proven their ability to help people lose weight safely over a period of months.”
“Earlier in March 2026, Novo Nordisk agreed to resume selling its weight-loss drugs through the Hims & Hers Health platform, ending a public legal conflict over copycat medications and restoring a commercial relationship in one of healthcare’s most competitive categories.”
“The renewed Novo Nordisk deal potentially reinforces the near term growth catalyst in weight loss, but it also highlights the biggest risk: heavy dependence on GLP‑1 and lifestyle categories where legal, competitive, and regulatory pressures can shift quickly.”
“Hims & Hers has had a rough go of it in 2026, but a recent deal with Novo Nordisk may bring the company's operations back to life.”
“Novo Nordisk and Hims & Hers renewed their commercial relationship, with plans for Ozempic and Wegovy, including pill and injection formats, to be available on the Hims & Hers platform.”
“Currently, Eli Lilly and Novo Nordisk dominate this space with their respective injectable therapies.”
“The approval made Wegovy the first GLP-1 therapy available as a pill for weight management, offering a needle-free alternative that could expand patient adoption.”